
Polyphor AG bags funding for murepavadin
Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

Avantium NV bags money for demo plant
The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...

Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

3P Bio to manufacture SpyBiotech vaccine
Under the agreement, Navarra-based CDMO 3P Biopharmaceuticals will produce cGMP lots for Phase I testing of SpyBiotech’s (Oxford) vaccine candidate...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...